Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Certolizumab Pegol in Active Axial Spondyloarthritis
2009-011719-19Phase 3Completed
- Sponsor
- UCB
- Start
- Feb 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS) and Spondylopathy (3 arms), sponsored by UCB. Started Feb 2010; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)Spondylopathy
Beyond the preview
Go deeper on 2009-011719-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011719-19.